Date:5/15/2012

NEW YORK, May 15, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019

http://www.reportlinker.com/p0606218/Neuroendocrine-Carcinoma-Therapeutics---Pipeline-Assessment-and-Market-Forecast-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019

Summary GlobalData, the industry analysis specialist, has released its new report, "Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019". The report is an essential source of information and analysis on the global neuroendocrine carcinoma market. The report identifies the key trends shaping and driving the market. It also provides insights on the prevalent competitive landscape and the emerging players that are expected to significantly alter the positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global neuroendocrine carcinoma sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData has estimated that the global neuroendocrine carcinoma therapeutics market was worth $127m in 2011 and is forecast to grow at Compound Annual Growth Rate (CAGR) of 17.9% to reach $475m by 2019. The high growth is primarily attributed to the advent of approved drugs, Sutent (sunitinib) and Afinitor (everolimus), in the major markets. The expected launch of promising drugs in the forecast period w
'/>"/>

SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related biology technology :

1. Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE
2. Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
3. Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood
4. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
5. SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
6. Targeted Gold Nanoparticles and Noninvasive Radio Fields Attacking One of the Deadliest and Least Curable Types of Cancer: Pancreatic Carcinoma
7. Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
8. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
9. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
10. Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy
11. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication